Journal of Nutrition LabDiet, Your World of Nutritional Answers

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qu, H.
Right arrow Articles by Wang, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qu, H.
Right arrow Articles by Wang, W.
© 2005 The American Society for Nutritional Sciences J. Nutr. 135:598-602, March 2005


Nutrition and Cancer

Lignans Are Involved in the Antitumor Activity of Wheat Bran in Colon Cancer SW480 Cells1,2

Hongyan Qu, Ronald L. Madl*, Dolores J. Takemoto{dagger}, Richard C. Baybutt and Weiqun Wang3

Department of Human Nutrition, * Department of Grain Science, and {dagger} Department of Biochemistry, Kansas State University, Manhattan, KS 66506

3To whom correspondence should be addressed. E-mail: wwang{at}ksu.edu.

Wheat bran was shown to provide protection against colorectal cancer in human intervention and animal studies. Our recent study showed, however, that antitumor activities of wheat bran from various wheat cultivars differed significantly even when wheat fiber was equal in diets. We hypothesized that phytochemical lignans in wheat bran may account for the differences among wheat cultivars in cancer prevention. The concentration of a major lignan, secoisolariciresinol diglycoside, was determined by HPLC in 4 selected wheat cultivars (i.e., Madison, Ernie, Betty, and Arapahoe). The lignan concentrations and their antitumor activities, previously determined in APC-Min mice, were correlated (r = 0.73, P < 0.02). The cancer preventive mechanisms of 2 prominent lignan metabolites (enterolactone and enterodiol) were further studied in human colonic cancer SW480 cells. Treatment with enterolactone and enterodiol, alone or in combination, at 0–40 µmol/L resulted in dose- and time-dependent decreases in cell numbers. Although the cytotoxicity as measured by trypan blue staining in adherent cells was not affected, DNA flow cytometric analysis indicated that the treatments induced cell cycle arrest at the S-phase. Western blot analysis for cyclin A, a required protein for S/G2 transition, showed that the cyclin A protein levels decreased after treatment with enterodiol or the combination of enterolactone and enterodiol at 40 µmol/L for 72 h. Apoptosis analysis by the terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling assay showed an increased percentage of apoptotic cells in the floating cells after enterodiol alone or combined treatments. These results suggest for the first time that lignans may contribute, at least in part, to the cancer prevention by wheat bran observed in APC-Min mice. Inhibition of cancer cell growth by lignan metabolites seems to be mediated by cytostatic and apoptotic mechanisms.


KEY WORDS: • lignans • wheat bran • SW480 colon cancer cells • cell cycle arrest • apoptosis




This article has been cited by other articles:


Home page
Am J EpidemiolHome page
A. Kuijsten, P. C. H. Hollman, H. C. Boshuizen, M. N. C. P. Buijsman, P. van 't Veer, F. J. Kok, I. C. W. Arts, and H. B. Bueno-de-Mesquita
Plasma Enterolignan Concentrations and Colorectal Cancer Risk in a Nested Case-Control Study
Am. J. Epidemiol., March 15, 2008; 167(6): 734 - 742.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L.-H. Chen, J. Fang, H. Li, W. Demark-Wahnefried, and X. Lin
Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway
Mol. Cancer Ther., September 1, 2007; 6(9): 2581 - 2590.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2005 by American Society for Nutrition